Member Info for Diversified

This valuation takes a discount to NPV into consideration when considering where it stands in its commercial pathway. Also a projected earnings multiple based on a peer comparison that would ordinarily see its peers valued in the billions.

Plenty of scope for upwards revision to TP

'@Stifel initiate coverage for @GenIncode with a BUY rating - "With US launch planned for 2022 and potential for sales to reach $225m by 2028E, we see significant upside to the shares." Target price 175p #GENI

A good starting point would be to refer to other IPO’s within the last several months to identify a particular pattern which in my opinion happens on a fairly regular basis.

From IPO you often see those that invested in the company when it was privately listed taking some profits as they are likely to have seen significant returns on capital following an IPO. It will then all depend on the commercial story, the news flow and broker forecasts.

For me the commercial pathway and news flow v market cap is what is so compelling about Geni and why within the next few weeks we should see a significant uplift in interest.

To date I have found all the answers to the questions I have been looking for, perseverance and persistence has assisted me in that endeavor. But I have no doubt that this upcoming investor meets will shine a new light on areas of the company that we haven’t yet considered.

Today’s broker note is a short term target only, but on the basis of a peer comparison when accessing valuation over the next 12 months should the main commercial milestones results in a positive outcome. It is clear to see the full potential here.

Cenkos initiates coverage at 73p in short term with significant upside potential.

De Novo application is imminent as we enter into a prior of significant news flow that will see additional coverage/revisions and an escalation in volume that will see this share rerate.

Personally, I expect 145p by end of tax year.

* Uk launch of Lipincode also expected Q3, should be a very busy end to the quarter and year end.

Agreed with a number of key catalysts coming in the short term including interim results, de novo submission for CardioIncode, paper on both Uk collaboration and the Covid study which should see the EUA submission for ThromboInCode.

All this and more to look forward to.

Broker note from Stifel, a highly encouraging write up

CardioIncode is the only test that has been validated with an evidence base of over 70,000 individuals from different population groups. This evidence base was subject to research and development costs of over €50m, with clinical trials and such like being performed over a 10 year period. With an enhanced and balanced patent portfolio, CardioIncode should be subject to a de novo application during the course of Q3 with ongoing discussions with the FDA only possible if it ultimately met the de novo criteria. With the average de novo timeline to a decision taking 241 days, the lead up to 2H 22” could IMO lead to a performance similar to that of AGL from 40p as news flow drives sentiment/volume.

CardioIncode test analyzes 170 genetic variants from blood or saliva, and when used in conjunction with SITAB. The Company’s SITAB system, a proprietary software, bioinformatics and algorithmic platform with online cloud-based reporting, is used to process and record test results and genetic information and, using algorithms and artificial intelligence, assesses a patient’s risk of a cardiovascular event. It reports results directly via a web portal to healthcare practitioners, cardiologists and physicians, in a user-friendly format.

It is also the only available genetic test for the assessment of cardiovascular risk that measures the patient’s genetic load and integrates it into the current risk profile of the patient.

Ultimately it is the evidence base and simplification of a genetic platform and integration of a sample to answer program (SITAB) to practitioners. This platform is well supported by the key opinion leaders within the sector that has created a barrier to entry of sorts, such as investment (€50m), time (10 years) and in turn an evidence base that is unrivaled on a like for like basis.

I understand a newly IPO’d company going through a period of extreme growth evidenced by the considerable commercialization plan over the next 12 months on multiple levels could justify a slower implementation plan of an investor relation department that isn’t otherwise walbrook. I can certainly forgive, overlook this in favor of such an exciting opportunity ahead.

It is this lack of understanding that has presented what is a modest valuation at best and presents a significant opportunity for those that are happy to do a deep dive into the companies prospects. Hope this helps.

My understanding is that we have multiple examples of Plc’s that have been listed for a material period of time which has allowed them to evolve their shareholder register over time. You may find that the share price has fluctuated through phased trials and respective dilution. In my opinion the difference with Geni and what the market has not become aware of to date is that Geni in the main is at a period of material shareholder value creation. To be approaching the FDA application this quarter having missed the €50m euros of development over time means that new shareholders are jumping the cue by comparison to the typical aim story, and it is this that hasn’t been fairly valued by the market to date.

In a nut shell, to have already received CE approval and made application for UK approval has somewhat derisked the opportunity, with an outcome from the FDA device designation also further derisking this opportunity. Those that participated in the raise would of done their due diligence to also consider this risk.

I can see this achieving 500% returns from here prior to the FDA decision. It’s been incredibly hard to maintain strict portfolio allocation discipline given the fantastic risk v reward opportunity here.

I just want to add, when looking at comparative valuations, how can E-therapeutics at £144m be worth considerably more than Geni? Other companies that are in the process of receiving an FDA decision such as AGL and POLX have market caps of £278m and £178m respectively.

Geni at £42m market cap with over £17m cash is quite simply on sale.

We know as a newly listed company, in most instances it can take several weeks for sufficient coverage to initiate a suitable level of interest to propel a companies profile and subsequent share price forward.

Within the next seven weeks we can expect at LEAST the following key milestones, regulated news updates to facilitate such a move.

1. FDA breakthrough device decision
2. FDA submission
3. Collaboration with Weill Cornell as part of the NYO

Significant background planning would have taken place to reach such milestones and with increased awareness to the company product mix, I am certain that this won’t remain quite for to much longer.

Patience is key.

At some point this really will be seen by the market and it should gain significant traction. Looks like current active posters have now portioned in expectation. GL.

Key takeaways:

- Share option plan - 2,868,000 between 4 directors - exercised at double the 44p IPO price after 30 consecutive days above this benchmark

How will they confidently attain this 2021 share option plan target without submission and successful outcome from the FDA and various authorities?

Newsflow:

- Cardio Incode - UKCA marking - Q1 22

- FDA breakthrough device - submitted May 21’ - decision Q3 21’ and ordinarily takes 60 days from submission so outcome should be imminent.

- 2 products subject to 2 initial clinical studies related to Covid 19 - would love to find out more info on progress and lead time for this.

- Forthcoming collaboration with Weill Cornell as part of the NYO

Additional stability is provided via a Lock in period of 12 months (42,522,182) - and institutional investors are considered long term according to their individual websites.

Market cap is simply to low for what has been invested to date and the many key milestones we can expect in the short term, including the physical submission to FDA via DE novo or 510(k).

I have a core investment in AGL from 42p and continue to hold, but this stock has enabled to to derisk some of the proceeds into this stock that is yet to get its story across to a growing number of private investors. I am certain from here the downside is limited and the upside could be many multiples.

Great summary and couldn’t agree more, the valuation of this company after cash is quite simply a steal, and for all the reasons you have emphasized, with additional coverage and newsflow this should rerate pretty quickly.

My theory is, and bear in mind my drilling knowledge is minimal. But if they started with a 100mm drill bit as per initial comms from company, and have since cased three times. (70/400/sidetrack), will they not now be on the smallest drill bit for the respective future casing? Thus they drill slow and conservatively, as any issues could prevent them reaching TD (although confirmed they are nearly at td on Friday Q&A)!

It may also explain why no further gas shows have been reported, as the gas show from 560m odd is interfering with possible shows lower down as a result if not being able to case again?

Pure speculation on my part as my google search implies that from 100mm there are only an additional three drill diameters. Thus caution.

Squeeze for eod finish 200/212p

I now fail to see how some fund managers make a living!?! If this isn’t a low risk high return opportunity then I am not sure what is?

What are we missing, I think the market wants to hear from the company with some detail of implications before the major rerate. Even so, to leave 70% upside from current prices on the table is far to much!

https://indiaaheadnews.com/india/retrospective-tax-amendment-how-cairn-versus-india-could-have-forced-a-rethink-40327/amp/?__twitter_impression=true

Put ‘Lok Sabha’, multiple sources from India confirming

https://t.co/dWGXMNKstf

Especially when the bill was officially passed within the last 15/20 minutes